These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(State or other jurisdiction of incorporation or organization)
|
|
(I.R.S. Employer Identification No.)
|
|
|
|
|||
|
|
,
|
|
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|||
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
|
|
|
|
|
|
|
|
|
Large accelerated filer
|
☐
|
|
☒
|
|
|
Non-accelerated filer
|
☐
|
Smaller reporting company
|
|
|
|
Emerging growth company
|
|
|||
|
i |
2024
FORM 10-K
|
||
|
|
|
|
|
|
Item 1.
|
|||
|
Item 1A.
|
|||
|
Item 1B.
|
|||
|
Item 1C.
|
Cybersecurity
|
||
|
Item 2.
|
|||
|
Item 3.
|
|||
|
Item 4.
|
|||
|
|
|
|
|
|
|
|
|
|
|
Item 5.
|
|||
|
Item 6.
|
Reserved
|
||
|
Item 7.
|
|||
|
Item 7A.
|
|||
|
Item 8.
|
|||
|
Item 9.
|
|||
|
Item 9A.
|
|||
|
Item 9B.
|
|||
|
Item 9C.
|
Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
|
||
|
|
|
|
|
|
|
|
|
|
|
Item 10.
|
|||
|
Item 11.
|
|||
|
Item 12.
|
|||
|
Item 13.
|
|||
|
Item 14.
|
|||
|
|
|
|
|
|
|
|
|
|
|
Item 15.
|
|||
|
Item 16.
|
|||
|
2 |
2024
FORM 10-K
|
FORWARD-LOOKING STATEMENTS
|
|
|
3 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
4 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
5 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
6 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
7 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
8 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
9 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
10 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
11 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
12 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
13 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
14 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
15 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
16 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
17 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
18 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
19 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
20 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
21 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
22 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
23 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
24 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
25 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
26 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
27 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
28 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
29 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
30 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
31 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
32 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
|
Retail
Stores
|
|
Retail
Stores
|
|
Retail
Stores
|
||
|
Alabama
|
10
|
Louisiana
|
11
|
Ohio
|
20
|
||
|
Alaska
|
1
|
Maine
|
3
|
Oklahoma
|
6
|
||
|
Arizona
|
15
|
Maryland
|
16
|
Oregon
|
8
|
||
|
Arkansas
|
8
|
Massachusetts
|
10
|
Pennsylvania
|
25
|
||
|
California
|
68
|
Michigan
|
20
|
Rhode Island
|
1
|
||
|
Colorado
|
15
|
Minnesota
|
16
|
South Carolina
|
10
|
||
|
Connecticut
|
6
|
Mississippi
|
5
|
South Dakota
|
2
|
||
|
Delaware
|
2
|
Missouri
|
12
|
Tennessee
|
15
|
||
|
Florida
|
46
|
Montana
|
4
|
Texas
|
58
|
||
|
Georgia
|
23
|
Nebraska
|
5
|
Utah
|
7
|
||
|
Hawaii
|
2
|
Nevada
|
6
|
Vermont
|
1
|
||
|
Idaho
|
3
|
New Hampshire
|
4
|
Virginia
|
20
|
||
|
Illinois
|
24
|
New Jersey
|
15
|
Washington
|
18
|
||
|
Indiana
|
14
|
New Mexico
|
4
|
West Virginia
|
3
|
||
|
Iowa
|
6
|
New York
|
21
|
Wisconsin
|
12
|
||
|
Kansas
|
5
|
North Carolina
|
21
|
Wyoming
|
2
|
||
|
Kentucky
|
9
|
North Dakota
|
2
|
||||
|
Total
|
640
|
|
33 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
34 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
Period
|
Total Number
of Shares
Purchased
(1)(2)
|
Average
Price
Paid per
Share
|
Total Number of
Shares Purchased
as Part of
Publicly
Announced Plans
or Programs
(1)
|
Approximate
Dollar Value of
Shares that May
Yet Be Purchased
Under the Plans
or Programs
(3)
|
||||
|
September 29, 2024 through October 26, 2024
|
205
|
$
14.65
|
—
|
$
348,071,000
|
||||
|
October 27, 2024 through November 23, 2024
|
1,530
|
$
12.34
|
—
|
348,071,000
|
||||
|
November 24, 2024 through December 28, 2024
|
891
|
$
19.84
|
—
|
348,071,000
|
||||
|
Total
|
2,626
|
$
15.07
|
—
|
$
348,071,000
|
|
35 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
|
12/28/19
|
01/02/21
|
01/01/22
|
12/31/22
|
12/30/23
|
12/28/24
|
|
Sleep Number Corporation
|
$
100
|
$
165
|
$
154
|
$
52
|
$
30
|
$
31
|
|
S&P 400 Specialty Stores Index
|
$
100
|
$
119
|
$
173
|
$
162
|
$
199
|
$
195
|
|
The Nasdaq Stock Market (U.S.) Index
|
$
100
|
$
145
|
$
177
|
$
118
|
$
170
|
$
223
|
|
36 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
37 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
38 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
39 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
2024
|
2023
|
2022
|
|||||||||
|
$
|
% of
Net
Sales
|
$
|
% of
Net
Sales
|
$
|
% of
Net Sales
|
||||||
|
Net sales
|
$
1,682.3
|
100.0%
|
$
1,887.5
|
100.0 %
|
$
2,114.3
|
100.0
%
|
|||||
|
Cost of sales
|
679.5
|
40.4%
|
799.0
|
42.3 %
|
912.0
|
43.1
%
|
|||||
|
Gross profit
|
1,002.8
|
59.6%
|
1,088.5
|
57.7 %
|
1,202.3
|
56.9
%
|
|||||
|
Operating expenses:
|
|||||||||||
|
Sales and marketing
|
766.6
|
45.6%
|
847.4
|
44.9 %
|
919.6
|
43.5
%
|
|||||
|
General and administrative
|
150.0
|
8.9%
|
146.6
|
7.8 %
|
153.3
|
7.2
%
|
|||||
|
Research and development
|
45.3
|
2.7%
|
55.8
|
3.0 %
|
61.5
|
2.9
%
|
|||||
|
Restructuring costs
|
18.1
|
1.1%
|
15.7
|
0.8 %
|
—
|
—
%
|
|||||
|
Total operating expenses
|
979.9
|
58.2%
|
1,065.6
|
56.5 %
|
1,134.4
|
53.7
%
|
|||||
|
Operating income
|
22.9
|
1.4%
|
22.9
|
1.2 %
|
67.9
|
3.2
%
|
|||||
|
Interest expense, net
|
48.4
|
2.9%
|
42.7
|
2.3 %
|
19.0
|
0.9
%
|
|||||
|
(Loss) income before income taxes
|
(25.5)
|
(1.5%)
|
(19.8)
|
(1.0 %)
|
48.9
|
2.3
%
|
|||||
|
Income tax (benefit) expense
|
(5.2)
|
(0.3%)
|
(4.5)
|
(0.2 %)
|
12.3
|
0.6
%
|
|||||
|
Net (loss) income
|
$
(20.3)
|
(1.2%)
|
$
(15.3)
|
(0.8 %)
|
$
36.6
|
1.7
%
|
|||||
|
Net (loss) income per share:
|
|||||||||||
|
Basic
|
$
(0.90)
|
$
(0.68)
|
$
1.63
|
||||||||
|
Diluted
|
$
(0.90)
|
$
(0.68)
|
$
1.60
|
||||||||
|
Weighted-average number of common shares:
|
|||||||||||
|
Basic
|
22.6
|
22.4
|
22.4
|
||||||||
|
Diluted
|
22.6
|
22.4
|
22.9
|
||||||||
|
2024
|
2023
|
2022
|
|||
|
Retail stores
|
87.6
%
|
86.8
%
|
86.3
%
|
||
|
Online, phone, chat and other
|
12.4
%
|
13.2
%
|
13.7
%
|
||
|
Total Company
|
100.0
%
|
100.0
%
|
100.0
%
|
|
Net Sales Increase/(Decrease)
|
|||||
|
2024
|
2023
|
2022
|
|||
|
Retail comparable-store sales
(1)
|
(9%)
|
(12%)
|
(8%)
|
||
|
Online, phone and chat
(1)
|
(17%)
|
(15%)
|
4%
|
||
|
Total Retail comparable sales change
(1)
|
(10%)
|
(12%)
|
(6%)
|
||
|
Net opened/closed stores and other
|
(1%)
|
1%
|
3%
|
||
|
Total Company
|
(11%)
|
(11%)
|
(3%)
|
||
|
40 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
2024
|
2023
|
2022
|
|||
|
Average sales per store ($ in thousands)
(1)
|
$
2,601
|
$
2,853
|
$
3,281
|
||
|
Average sales per square foot
(1)
|
$
841
|
$
926
|
$
1,081
|
||
|
Stores > $2 million in net sales
(2)
|
57
%
|
65
%
|
76
%
|
||
|
Stores > $3 million in net sales
(2)
|
18
%
|
24
%
|
36
%
|
||
|
Average revenue per smart bed unit – Total Retail
(3)
|
$
5,818
|
$
5,755
|
$
5,403
|
|
2024
|
2023
|
2022
|
|||
|
Beginning of period
|
672
|
670
|
648
|
||
|
Opened
|
12
|
36
|
49
|
||
|
Closed
|
(44)
|
(34)
|
(27)
|
||
|
End of period
|
640
|
672
|
670
|
|
41 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
42 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
2024
|
2023
|
||
|
Total cash provided by (used in):
|
|||
|
Operating activities
|
$
27,143
|
$
(9,028)
|
|
|
Investing activities
|
(26,291)
|
(58,352)
|
|
|
Financing activities
|
(1,441)
|
68,127
|
|
|
Net (decrease) increase in cash and cash equivalents
|
$
(589)
|
$
747
|
|
43 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
44 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
|
Year
|
|||||
|
|
2024
|
2023
|
2022
|
|||
|
Net (loss) income
|
$
(20,334)
|
$
(15,287)
|
$
36,610
|
|||
|
Income tax (benefit) expense
|
(5,162)
|
(4,466)
|
12,285
|
|||
|
Interest expense
|
48,368
|
42,695
|
18,985
|
|||
|
Depreciation and amortization
|
64,979
|
72,479
|
66,626
|
|||
|
Stock-based compensation
|
11,444
|
14,855
|
13,223
|
|||
|
Restructuring costs
(1)
|
18,066
|
15,728
|
—
|
|||
|
CEO transition/Proxy contest costs
(2)
|
998
|
—
|
—
|
|||
|
Asset impairments
|
1,220
|
672
|
295
|
|||
|
Adjusted EBITDA
|
$
119,579
|
$
126,676
|
$
148,024
|
|||
|
|
Year
|
||||
|
|
2024
|
2023
|
2022
|
||
|
Net cash provided by (used in) operating activities
|
$
27,143
|
$
(9,028)
|
$
36,138
|
||
|
Subtract: Purchases of property and equipment
|
(23,505)
|
(57,056)
|
(69,454)
|
||
|
Free cash flow
|
$
3,638
|
$
(66,084)
|
$
(33,316)
|
||
|
45 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
|
Year
|
||||
|
|
2024
|
2023
|
2022
|
||
|
Adjusted net operating profit after taxes (Adjusted NOPAT)
|
|
||||
|
Operating income
|
$
22,872
|
$
22,942
|
$
67,880
|
||
|
Add: Operating lease interest
(1)
|
26,775
|
27,777
|
25,912
|
||
|
Less: Income taxes
(2)
|
(11,907)
|
(11,851)
|
(23,542)
|
||
|
Adjusted NOPAT
|
$
37,740
|
$
38,868
|
$
70,250
|
||
|
Average adjusted invested capital
|
|||||
|
Total deficit
|
$
(451,586)
|
$
(441,928)
|
$
(438,177)
|
||
|
Add: Long-term debt
(3)
|
546,841
|
539,819
|
460,020
|
||
|
Add: Operating lease obligations
(4)
|
389,508
|
433,154
|
436,412
|
||
|
Total adjusted invested capital at end of period
|
$
484,763
|
$
531,045
|
$
458,255
|
||
|
Average adjusted invested capital
(5)
|
$
497,972
|
$
496,612
|
$
400,038
|
||
|
Adjusted return on invested capital (Adjusted ROIC)
|
7.6
%
|
7.8
%
|
17.6
%
|
||
|
46 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
Description
|
Judgments and Uncertainties
|
Effect if Actual Results
Differ from Assumptions
|
||
|
Stock-Based Compensation
|
|
|
||
|
The Company has stock-based
compensation plans, which include non-
qualified stock options and stock
awards.
See Note 1,
Business and Summary of
Significant Accounting Policies
, and
Note 8,
Shareholders’ Deficit
, to the
Notes to Consolidated Financial
Statements, included in Item 8,
Financial
Statements and Supplementary Data
, of
this Annual Report on Form 10-K, for a
complete discussion of its stock-based
compensation programs.
|
Option-pricing models and generally
accepted valuation techniques require
management to make assumptions and
to apply judgment to determine the fair
value of the awards. These assumptions
and judgments include estimating the
volatility of its stock price, future
employee forfeiture rates and future
employee stock option exercise
behaviors. Changes in these
assumptions can materially affect the
fair value estimates or future earnings
adjustments.
Performance-based stock awards
require management to make
assumptions regarding the likelihood of
achieving performance targets.
|
The Company does not believe there is
a reasonable likelihood that there will
be a material change in the future
estimates or assumptions it uses to
determine stock-based compensation
expense. However, if actual results are
not consistent with its estimates or
assumptions, the Company may be
exposed to changes in stock-based
compensation expense that could be
material.
In addition, if actual results are not
consistent with the assumptions used,
the stock-based compensation expense
reported in its financial statements may
not be representative of the actual
economic cost of the stock-based
compensation. Finally, if the actual
forfeiture rates, or the actual
achievement of performance targets,
are not consistent with the assumptions
used, the Company could experience
future earnings adjustments.
A 10% change in its stock-based
compensation expense for the year
ended
December 28, 2024
, would have
affected net loss by approximately
$0.9 million in
2024
.
|
||
|
47 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
Description
|
Judgments and Uncertainties
|
Effect if Actual Results
Differ from Assumptions
|
||
|
Warranty Liabilities
|
|
|||
|
The Company provides a limited
warranty on most of the products it
sells.
See Note 1,
Business and Summary of
Significant Accounting Policies
, to the
Notes to Consolidated Financial
Statements, included in Item 8,
Financial
Statements and Supplementary Data
, of
this Annual Report on Form 10-K, for a
complete discussion of its warranty
program and liabilities.
|
The majority of its warranty claims are
incurred within the first year. However,
the Company’s warranty liability
contains uncertainties because its
warranty obligations cover an extended
period of time. A revision of estimated
claim rates or the projected cost of
materials and freight associated with
sending replacement parts to customers
could have a material adverse effect on
future results of operations.
|
The Company has not made any
material changes in its warranty liability
assessment methodology during the
past three fiscal years. The Company
does not believe there is a reasonable
likelihood that there will be a material
change in the estimates or assumptions
it uses to calculate its warranty liability.
However, if actual results are not
consistent with its estimates or
assumptions, the Company may be
exposed to losses or gains that could be
material.
A 10% change in its warranty liability at
December 28, 2024
, would have
affected net loss by approximately
$0.5 million in
2024
.
|
||
|
Revenue Recognition
|
||||
|
Certain accounting estimates relating to
revenue recognition contain uncertainty
because they require management to
make assumptions and to apply
judgment regarding the effects of future
events.
See Note 1,
Business and Summary of
Significant Accounting Policies
, and
Note 9,
Revenue Recognition
, to the
Notes to Consolidated Financial
Statements, included in Item 8,
Financial
Statements and Supplementary Data
, of
this Annual Report on Form 10-K, for a
complete discussion of its revenue
recognition policies.
|
The Company’s estimates of sales
returns contain uncertainties as actual
sales return rates may vary from
expected rates, resulting in adjustments
to net sales in future periods. These
adjustments could have an adverse
effect on future results of operations.
|
The Company has not made any
material changes in the accounting
methodology used to establish its sales
returns allowance during the past three
fiscal years. The Company does not
believe there is a reasonable likelihood
that there will be a material change in
the estimates or assumptions it uses to
calculate its sales returns allowance.
However, if actual results are not
consistent with its estimates or
assumptions, the Company may be
exposed to additional losses or gains in
future periods.
A 10% change in its sales returns
allowance at
December 28, 2024
would
have affected net loss by approximately
$1.5 million in
2024
.
|
|
48 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
49 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
50 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
51 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
|
2024
|
2023
|
|
|
Assets
|
|||
|
Current assets:
|
|||
|
Cash and cash equivalents
|
$
|
$
|
|
|
Accounts receivable, net of allowances of
$
|
|
|
|
|
Inventories
|
|
|
|
|
Prepaid expenses
|
|
|
|
|
Other current assets
|
|
|
|
|
Total current assets
|
|
|
|
|
Non-current assets:
|
|||
|
Property and equipment, net
|
|
|
|
|
Operating lease right-of-use assets
|
|
|
|
|
Goodwill and intangible assets, net
|
|
|
|
|
Deferred income taxes
|
|
|
|
|
Other non-current assets
|
|
|
|
|
Total assets
|
$
|
$
|
|
|
Liabilities and Shareholders’ Deficit
|
|||
|
Current liabilities:
|
|||
|
Borrowings under revolving credit facility
|
$
|
$
|
|
|
Accounts payable
|
|
|
|
|
Customer prepayments
|
|
|
|
|
Accrued sales returns
|
|
|
|
|
Compensation and benefits
|
|
|
|
|
Taxes and withholding
|
|
|
|
|
Operating lease liabilities
|
|
|
|
|
Other current liabilities
|
|
|
|
|
Total current liabilities
|
|
|
|
|
Non-current liabilities:
|
|||
|
Operating lease liabilities
|
|
|
|
|
Other non-current liabilities
|
|
|
|
|
Total liabilities
|
|
|
|
|
Shareholders’ deficit:
|
|||
|
Undesignated preferred stock;
outstanding
|
|
|
|
|
Common stock,
$
shares issued and outstanding, respectively
|
|
|
|
|
Additional paid-in capital
|
|
|
|
|
Accumulated deficit
|
(
|
(
|
|
|
Total shareholders’ deficit
|
(
|
(
|
|
|
Total liabilities and shareholders’ deficit
|
$
|
$
|
|
52 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
|
2024
|
2023
|
2022
|
||
|
Net sales
|
$
|
$
|
$
|
||
|
Cost of sales
|
|
|
|
||
|
Gross profit
|
|
|
|
||
|
Operating expenses:
|
|||||
|
Sales and marketing
|
|
|
|
||
|
General and administrative
|
|
|
|
||
|
Research and development
|
|
|
|
||
|
Restructuring costs
|
|
|
|
||
|
Total operating expenses
|
|
|
|
||
|
Operating income
|
|
|
|
||
|
Interest expense, net
|
|
|
|
||
|
(Loss) income before income taxes
|
(
|
(
|
|
||
|
Income tax (benefit) expense
|
(
|
(
|
|
||
|
Net (loss) income
|
$
(
|
$
(
|
$
|
||
|
Basic net (loss) income per share:
|
|||||
|
Net (loss) income per share – basic
|
$
(
|
$
(
|
$
|
||
|
Weighted-average shares – basic
|
|
|
|
||
|
Diluted net (loss) income per share:
|
|||||
|
Net (loss) income per share – diluted
|
$
(
|
$
(
|
$
|
||
|
Weighted-average shares – diluted
|
|
|
|
|
53 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
|
Common Stock
|
Additional
Paid-in
Capital
|
Accumulated
Deficit
|
|
|||||
|
|
Shares
|
Amount
|
Total
|
||||||
|
Balance at January 1, 2022
|
|
$
|
$
|
$
(
|
$
(
|
||||
|
Net income
|
—
|
—
|
—
|
|
|
||||
|
Exercise of common stock options
|
|
|
|
—
|
|
||||
|
Stock-based compensation
|
|
|
|
—
|
|
||||
|
Repurchases of common stock
|
(
|
(
|
(
|
(
|
(
|
||||
|
Balance at December 31, 2022
|
|
$
|
$
|
$
(
|
$
(
|
||||
|
Net loss
|
—
|
—
|
—
|
(
|
(
|
||||
|
Exercise of common stock options
|
|
—
|
|
—
|
|
||||
|
Stock-based compensation
|
|
|
|
—
|
|
||||
|
Repurchases of common stock
|
(
|
(
|
(
|
|
(
|
||||
|
Balance at December 30, 2023
|
|
$
|
$
|
$
(
|
$
(
|
||||
|
Net loss
|
—
|
—
|
—
|
(
|
(
|
||||
|
Exercise of common stock options
|
|
—
|
|
—
|
|
||||
|
Stock-based compensation
|
|
|
|
—
|
|
||||
|
Repurchases of common stock
|
(
|
(
|
(
|
—
|
(
|
||||
|
Balance at December 28, 2024
|
|
$
|
$
|
$
(
|
$
(
|
||||
|
54 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
|
2024
|
2023
|
2022
|
||
|
Cash flows from operating activities:
|
|||||
|
Net (loss) income
|
$
(
|
$
(
|
$
|
||
|
Adjustments to reconcile net (loss) income to net cash provided
by operating activities:
|
|||||
|
Depreciation and amortization
|
|
|
|
||
|
Stock-based compensation
|
|
|
|
||
|
Net loss on disposals and impairments of assets
|
|
|
|
||
|
Deferred income taxes
|
(
|
(
|
(
|
||
|
Changes in operating assets and liabilities:
|
|||||
|
Accounts receivable
|
|
(
|
(
|
||
|
Inventories
|
|
(
|
(
|
||
|
Income taxes
|
|
(
|
|
||
|
Prepaid expenses and other assets
|
(
|
(
|
|
||
|
Accounts payable
|
(
|
(
|
(
|
||
|
Customer prepayments
|
(
|
(
|
(
|
||
|
Accrued compensation and benefits
|
|
(
|
(
|
||
|
Other taxes and withholding
|
(
|
(
|
|
||
|
Other accruals and liabilities
|
(
|
(
|
(
|
||
|
Net cash provided by (used in) operating activities
|
|
(
|
|
||
|
Cash flows from investing activities:
|
|||||
|
Purchases of property and equipment
|
(
|
(
|
(
|
||
|
Proceeds from sales of property and equipment
|
|
|
|
||
|
Issuance of notes receivable
|
(
|
(
|
|
||
|
Investment in non-marketable equity securities
|
|
|
(
|
||
|
Net cash used in investing activities
|
(
|
(
|
(
|
||
|
Cash flows from financing activities:
|
|||||
|
Repurchases of common stock
|
(
|
(
|
(
|
||
|
Net (decrease) increase in short-term borrowings
|
(
|
|
|
||
|
Proceeds from issuance of common stock
|
|
|
|
||
|
Debt issuance costs
|
|
(
|
(
|
||
|
Net cash (used in) provided by financing activities
|
(
|
|
|
||
|
Net (decrease) increase in cash and cash equivalents
|
(
|
|
(
|
||
|
Cash and cash equivalents, at beginning of period
|
|
|
|
||
|
Cash and cash equivalents, at end of period
|
$
|
$
|
$
|
||
|
Supplemental Disclosure of Cash Flow Information
|
|||||
|
Income taxes paid, net of refunds
|
$
|
$
|
$
|
||
|
Interest paid
|
$
|
$
|
$
|
||
|
Purchases of property and equipment included in accounts
payable
|
$
|
$
|
$
|
|
55 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
56 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
Leasehold improvements
|
|
|
Furniture and equipment
|
|
|
Production machinery
|
|
|
Computer equipment and software
|
|
|
57 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
|
2024
|
2023
|
2022
|
||
|
Balance at beginning of period
|
$
|
$
|
$
|
||
|
Additions charged to costs and expenses for current-year sales
|
|
|
|
||
|
Deductions from reserves
|
(
|
(
|
(
|
||
|
Change in liabilities for pre-existing warranties during the current
year, including expirations
|
(
|
|
(
|
||
|
Balance at end of period
|
$
|
$
|
$
|
|
58 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
59 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
Cost of Sales
|
Sales & Marketing
|
|||
|
•
|
Costs associated with purchasing, manufacturing, shipping,
handling and delivering the Company’s products to its retail
stores and customers, including payroll and benefits;
|
•
|
Advertising, marketing and media production;
|
|
|
•
|
Marketing and selling materials such as brochures, videos,
websites, customer mailings and in-store signage;
|
|||
|
•
|
Physical inventory losses, scrap and obsolescence;
|
•
|
Payroll and benefits for sales and customer service staff;
|
|
|
•
|
Related occupancy and depreciation expenses;
|
•
|
Store occupancy costs;
|
|
|
•
|
Costs associated with returns and exchanges; and
|
•
|
Store depreciation expense;
|
|
|
•
|
Estimated costs to service customer warranty claims.
|
•
|
Credit card processing fees; and
|
|
|
•
|
Promotional financing costs.
|
|||
|
G&A
|
R&D
(1)
|
|||
|
•
|
Payroll and benefit costs for corporate employees, including
information technology, legal, human resources, finance, sales
and marketing administration, investor relations and risk
management;
|
•
|
Internal labor and benefits related to research and
development activities;
|
|
|
•
|
Outside consulting services related to research and
development activities; and
|
|||
|
•
|
Occupancy costs of corporate facilities;
|
•
|
Testing equipment related to research and development
|
|
|
•
|
Depreciation related to corporate assets;
|
___________________________
(1)
Costs incurred in connection with R&D are charged to expense as incurred.
|
||
|
•
|
Information hardware, software and maintenance;
|
|||
|
•
|
Insurance;
|
|||
|
•
|
Investor relations costs; and
|
|||
|
•
|
Other overhead costs.
|
|
60 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
61 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
62 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
63 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
|
December 28,
2024
|
December 30,
2023
|
|
|
Raw Materials
|
$
|
$
|
|
|
Work in Progress
|
|
|
|
|
Finished goods
|
|
|
|
|
$
|
$
|
|
64 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
|
December 28,
2024
|
December 30,
2023
|
|
|
Finished beds, including deliveries in-transit to those customers who have utilized
home delivery services
|
$
|
$
|
|
|
Finished components that were ready for assembly for the completion of beds
|
|
|
|
|
Retail accessories
|
|
|
|
|
|
$
|
$
|
|
|
December 28,
2024
|
December 30,
2023
|
|
|
Leasehold improvements
|
$
|
$
|
|
|
Furniture and equipment
|
|
|
|
|
Production machinery, computer equipment and software
|
|
|
|
|
Construction in progress
|
|
|
|
|
Less: Accumulated depreciation and amortization
|
(
|
(
|
|
|
$
|
$
|
|
December 28, 2024
|
December 30, 2023
|
||||||
|
Gross Carrying
Amount
|
Accumulated
Amortization
|
Gross Carrying
Amount
|
Accumulated
Amortization
|
||||
|
Developed technologies
|
$
|
$
|
$
|
$
|
|||
|
Patents
|
|
|
|
|
|||
|
$
|
$
|
$
|
$
|
||||
|
65 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
2025
|
$
|
|
2026
|
|
|
2027
|
|
|
2028
|
|
|
2029
|
|
|
Thereafter
|
|
|
Total future amortization for definite-lived intangible assets
|
$
|
|
66 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
|
December 28,
2024
|
December 30,
2023
|
|
|
Outstanding borrowings
|
$
|
$
|
|
|
Outstanding letters of credit
|
$
|
$
|
|
|
Additional borrowing capacity
|
$
|
$
|
|
|
Weighted-average interest rate
|
|
|
|
67 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
2024
|
2023
|
2022
|
|||
|
Operating lease costs
(1)
|
$
|
$
|
$
|
||
|
Variable lease costs
|
$
|
$
|
$
|
|
2025
|
$
|
|
2026
|
|
|
2027
|
|
|
2028
|
|
|
2029
|
|
|
Thereafter
|
|
|
Total operating lease payments
(2)
|
|
|
Less: Interest
|
|
|
Present value of operating lease liabilities
|
$
|
|
|
December 28,
2024
|
December 30,
2023
|
||
|
Weighted-average remaining lease term (years)
|
|
|
||
|
Weighted-average discount rate
|
|
|
|
(in thousands)
|
2024
|
2023
|
2022
|
|||
|
Cash paid for amounts included in present value of operating
lease liabilities
|
$
|
$
|
$
|
|||
|
Right-of-use assets obtained in exchange for operating lease
liabilities
|
$
|
$
|
$
|
|
68 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
|
2024
|
2023
|
2022
|
||
|
Stock awards
(1)
|
$
|
$
|
$
|
||
|
Stock options
|
|
|
|
||
|
Total stock-based compensation expense
(1)
|
|
|
|
||
|
Income tax benefit
|
|
|
|
||
|
Total stock-based compensation expense, net of tax
|
$
|
$
|
$
|
|
|
Stock
Options
|
Weighted-
Average
Exercise
Price per
Share
|
Weighted-
Average
Remaining
Contractual
Term (years)
|
Aggregate
Intrinsic
Value
(1)
|
|||
|
Outstanding at December 30, 2023
|
|
$
|
|
$
|
|||
|
Granted
|
|
|
|||||
|
Exercised
|
|
|
|||||
|
Canceled/Forfeited
|
(
|
|
|||||
|
Outstanding at December 28, 2024
|
|
$
|
|
$
|
|||
|
Exercisable at December 28, 2024
|
|
$
|
|
$
|
|||
|
Vested and expected to vest at December 28, 2024
|
|
$
|
|
$
|
|
|
2024
|
2023
|
2022
|
||
|
Weighted-average grant date fair value of stock options granted
|
$
|
$
|
$
|
||
|
Total intrinsic value (at exercise) of stock options exercised
|
$
|
$
|
$
|
|
69 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
Valuation Assumptions
|
2024
|
2023
|
2022
|
||
|
Expected dividend yield
|
|
|
|
||
|
Expected volatility
|
|
|
|
||
|
Risk-free interest rate
|
|
|
|
||
|
Expected term (years)
|
—
|
|
|
|
Time-
Based
Stock
Awards
|
Weighted-
Average
Grant Date
Fair Value
|
Performance-
Based
Stock Awards
|
Weighted-
Average
Grant Date
Fair Value
|
||||
|
Outstanding at December 30, 2023
|
|
$
|
|
$
|
|||
|
Granted
|
|
|
|
|
|||
|
Vested
|
(
|
|
(
|
|
|||
|
Canceled/Forfeited
|
(
|
|
(
|
|
|||
|
Outstanding at December 28, 2024
|
|
$
|
|
$
|
|
|
2024
|
2023
|
2022
|
||
|
Amount repurchased under Board-approved share repurchase
program
|
$
|
$
|
$
|
||
|
Amount repurchased in connection with the vesting of employee
restricted stock grants
|
|
|
|
||
|
Total amount repurchased (based on trade dates)
|
$
|
$
|
$
|
|
70 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
|
2024
|
2023
|
2022
|
||
|
Net (loss) income
|
$
(
|
$
(
|
$
|
||
|
Reconciliation of weighted-average shares outstanding:
|
|||||
|
Basic weighted-average shares outstanding
|
|
|
|
||
|
Dilutive effect of stock-based awards
|
|
|
|
||
|
Diluted weighted-average shares outstanding
|
|
|
|
||
|
Net (loss) income per share – basic
|
$
(
|
$
(
|
$
|
||
|
Net (loss) income per share – diluted
|
$
(
|
$
(
|
$
|
|
|
December 28,
2024
|
December 30,
2023
|
|
|
Deferred contract assets included in:
|
|
|
|
|
Other current assets
|
$
|
$
|
|
|
Other non-current assets
|
|
|
|
|
|
$
|
$
|
|
|
December 28,
2024
|
December 30,
2023
|
|
|
Deferred contract liabilities included in:
|
|
|
|
|
Other current liabilities
|
$
|
$
|
|
|
Other non-current liabilities
|
|
|
|
|
|
$
|
$
|
|
71 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
|
2024
|
2023
|
2022
|
||
|
Retail stores
|
$
|
$
|
$
|
||
|
Online, phone, chat and other
|
|
|
|
||
|
Total Company
|
$
|
$
|
$
|
|
|
2024
|
2023
|
|
|
Balance at beginning of year
|
$
|
$
|
|
|
Additions that reduce net sales
|
|
|
|
|
Deduction from reserves
|
(
|
(
|
|
|
Balance at end of period
|
$
|
$
|
|
2024
|
2023
|
||||
|
Cash restructuring costs:
|
|||||
|
Contract termination costs
(1)
|
$
|
$
|
|||
|
Severance and employee-related benefits
|
|
|
|||
|
Professional fees and other
|
|
|
|||
|
Total cash restructuring costs
|
|
|
|||
|
Non-cash restructuring costs:
|
|||||
|
Asset impairments
(2)
|
|
|
|||
|
Total restructuring costs
|
$
|
$
|
|
72 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
2024
|
2023
|
||||
|
Balance at December 30, 2023
|
$
|
$
|
|||
|
Expenses
|
|
|
|||
|
Cash payments
|
(
|
(
|
|||
|
Balance at December 28, 2024
|
$
|
$
|
|
Cumulative
|
||||
|
December 28, 2024
|
||||
|
Cash restructuring costs:
|
||||
|
Contract termination costs
(1)
|
$
|
|||
|
Severance and employee-related benefits
|
|
|||
|
Professional fees and other
|
|
|||
|
Total cash restructuring costs
|
|
|||
|
Non-cash restructuring costs:
|
||||
|
Asset impairments
(2)
|
|
|||
|
Total restructuring costs
|
$
|
|
2024
|
2023
|
2022
|
|||
|
Current:
|
|||||
|
Federal
|
$
|
$
|
$
|
||
|
State
|
|
|
|
||
|
|
|
|
|||
|
Deferred:
|
|||||
|
Federal
|
(
|
(
|
(
|
||
|
State
|
(
|
(
|
(
|
||
|
(
|
(
|
(
|
|||
|
Income tax (benefit) expense
|
$
(
|
$
(
|
$
|
|
73 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
2024
|
2023
|
2022
|
|||
|
Statutory federal income tax
|
|
|
|
||
|
State income taxes, net of federal benefit
|
|
(
|
|
||
|
R&D tax credits
|
|
|
(
|
||
|
Return to provision
|
|
|
|
||
|
Investment tax credit
|
|
|
|
||
|
Stock-based compensation
|
(
|
(
|
(
|
||
|
Non-deductible compensation
|
(
|
(
|
|
||
|
Non-deductible expenses
|
(
|
(
|
|
||
|
Changes in unrecognized tax benefits
|
(
|
(
|
(
|
||
|
Valuation allowance
|
(
|
|
|
||
|
Other
|
|
(
|
|
||
|
Effective income tax rate
|
|
|
|
|
2024
|
2023
|
||
|
Deferred tax assets:
|
|||
|
Stock-based compensation
|
$
|
$
|
|
|
Operating lease liabilities
|
|
|
|
|
Warranty and returns liabilities
|
|
|
|
|
Net operating loss carryforwards and credits
|
|
|
|
|
Compensation and benefits
|
|
|
|
|
Research and development
|
|
|
|
|
Interest
|
|
|
|
|
Other
|
|
|
|
|
Total gross deferred tax assets
|
|
|
|
|
Valuation allowance
|
(
|
(
|
|
|
Total gross deferred tax assets after valuation allowance
|
|
|
|
|
Deferred tax liabilities:
|
|||
|
Property and equipment
|
|
|
|
|
Operating lease right-of-use assets
|
|
|
|
|
Deferred revenue
|
|
|
|
|
Other
|
|
|
|
|
Total gross deferred tax liabilities
|
|
|
|
|
Net deferred tax assets
|
$
|
$
|
|
74 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
Federal and State Tax
|
|||||
|
2024
|
2023
|
2022
|
|||
|
Beginning balance
|
$
|
$
|
$
|
||
|
Increases related to current-year tax positions
|
|
|
|
||
|
Increases related to prior-year tax positions
|
|
|
|
||
|
Decreases related to prior-year tax positions
|
(
|
|
(
|
||
|
Lapse of statute of limitations
|
(
|
(
|
(
|
||
|
Settlements with taxing authorities
|
|
(
|
|
||
|
Ending balance
|
$
|
$
|
$
|
||
|
75 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
2024
|
2023
|
2022
|
|||
|
Net Sales
|
$
|
$
|
$
|
||
|
Less:
|
|||||
|
Cost of sales
|
(
|
(
|
(
|
||
|
Marketing expenses
|
(
|
(
|
(
|
||
|
Selling expenses
|
(
|
(
|
(
|
||
|
General and administrative
|
(
|
(
|
(
|
||
|
Research and development
|
(
|
(
|
(
|
||
|
Restructuring costs
|
(
|
(
|
|
||
|
Asset impairment charges
|
(
|
(
|
|
||
|
Interest expense
|
(
|
(
|
(
|
||
|
Income tax benefit (expense)
|
|
|
(
|
||
|
Net (loss) income
|
$
(
|
$
(
|
$
|
|
76 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
77 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
78 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
79 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
80 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
Exhibit
No.
|
Description
|
||
|
3.1
|
|||
|
3.2
|
|||
|
3.3
|
|||
|
3.4
|
|||
|
3.5
|
|||
|
4.1
|
|||
|
10.1
|
|||
|
10.2
|
|||
|
10.3
|
|
||
|
10.4
|
|
||
|
10.5
|
|
||
|
10.6
|
|
||
|
10.7
|
|
||
|
10.8*
|
|
81 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
Exhibit
No.
|
Description
|
||
|
10.9
†
|
|||
|
10.10
†
|
|||
|
10.11
†
|
|
||
|
10.12
†
|
|
||
|
10.13
†
|
|||
|
10.14
†
|
|||
|
10.15
†
|
|||
|
10.16
†
|
|||
|
10.17
†
|
|||
|
10.18
†
|
|||
|
10.19
†
|
|||
|
10.20
†
|
|||
|
10.21
|
|
||
|
10.22
|
|
|
82 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
Exhibit
No.
|
Description
|
||
|
10.23
|
|
||
|
10.24
|
|
||
|
10.25
|
|
||
|
10.26
|
|
||
|
10.27
|
|
||
|
10.28
|
|||
|
10.29*
|
|||
|
10.30
†
|
|||
|
10.31†
|
|||
|
10.32†
|
|||
|
10.33†
|
|||
|
10.34†
|
|||
|
10.35†
|
|
||
|
10.36
†
|
|
83 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
Exhibit
No.
|
Description
|
||
|
10.37
†
|
|
||
|
10.38
†
|
|||
|
10.39
†
|
|||
|
10.40
†
|
|
||
|
10.41†
|
|
||
|
10.42†*
|
|||
|
10.43†*
|
|||
|
10.44
†
|
|||
|
10.45
†
|
|||
|
10.46
†
|
|||
|
10.47
†
|
|||
|
19.1*
|
|||
|
21.1*
|
|||
|
23.1*
|
|||
|
24.1*
|
|||
|
31.1*
|
|||
|
31.2*
|
|||
|
32.1*
|
|||
|
32.2*
|
|||
|
97.1
†
|
|
84 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
Exhibit
No.
|
Description
|
||
|
101.INS*
|
Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File
because its XBRL tags are embedded within the Inline XBRL document
|
||
|
101.SCH*
|
Inline XBRL Taxonomy Extension Schema Document
|
||
|
101.CAL*
|
Inline XBRL Taxonomy Extension Calculation Linkbase Document
|
||
|
101.DEF*
|
Inline XBRL Taxonomy Extension Definition Linkbase Document
|
||
|
101.LAB*
|
Inline XBRL Taxonomy Extension Label Linkbase Document
|
||
|
101.PRE*
|
Inline XBRL Taxonomy Extension Presentation Linkbase Document
|
||
|
104*
|
Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)
|
|
85 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
SLEEP NUMBER CORPORATION
|
|||
|
(Registrant)
|
|||
|
March 7, 2025
|
By:
|
/s/ Shelly R. Ibach
|
|
|
Shelly R. Ibach
|
|||
|
Chief Executive Officer
|
|||
|
(principal executive officer)
|
|||
|
By:
|
/s/ Francis K. Lee
|
||
|
Francis K. Lee
|
|||
|
Chief Financial Officer
|
|||
|
(principal financial officer)
|
|||
|
By:
|
/s/ Joel J. Laing
|
||
|
Joel J. Laing
|
|||
|
Chief Accounting Officer
|
|||
|
(principal accounting officer)
|
|||
|
86 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
Name
|
Title
|
Date
|
||
|
/s/ Shelly R. Ibach
|
Chair of the Board
|
March 7, 2025
|
||
|
Shelly R. Ibach
|
||||
|
/s/ Phillip M. Eyler
|
Director
|
March 6, 2025
|
||
|
Phillip M. Eyler
|
||||
|
/s/ Stephen L. Gulis, Jr.
|
Director
|
March 4, 2025
|
||
|
Stephen L. Gulis, Jr.
|
||||
|
/s/ Michael J. Harrison
|
Director
|
March 4, 2025
|
||
|
Michael J. Harrison
|
||||
|
/s/ Julie M. Howard
|
Director
|
March 5, 2025
|
||
|
Julie M. Howard
|
||||
|
/s/ Deborah L. Kilpatrick
|
Director
|
March 3, 2025
|
||
|
Deborah L. Kilpatrick
|
||||
|
/s/ Brenda J. Lauderback
|
Director
|
March 6, 2025
|
||
|
Brenda J. Lauderback
|
||||
|
/s/ Stephen E. Macadam
|
Director
|
March 4, 2025
|
||
|
Stephen E. Macadam
|
||||
|
/s/ Barbara R. Matas
|
Director
|
March 4, 2025
|
||
|
Barbara R. Matas
|
||||
|
/s/ Angel L. Mendez
|
Director
|
March 4, 2025
|
||
|
Angel L. Mendez
|
||||
|
/s/Hilary A. Schneider
|
Director
|
March 3, 2025
|
||
|
Hilary A. Schneider
|
|
87 |
2024
FORM 10-K
|
SLEEP NUMBER CORPORATION
|
|
|
Description
|
2024
|
2023
|
2022
|
|||
|
Allowances for credit losses
|
||||||
|
Balance at beginning of period
|
$
|
$
|
$
|
|||
|
Additions charged to costs and expenses
|
|
|
|
|||
|
Deductions from reserves
|
(
|
(
|
(
|
|||
|
Balance at end of period
|
$
|
$
|
$
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|